Ability to Reverse Deeper Levels of Unintended SedationMorse J.a · Bamias G.b
aCowichan District Hospital, Duncan, B.C., Canada; b1st Department of Internal Medicine – Propaedeutic, Laiko General Hospital of Athens, Athens, Greece Corresponding Author
Cowichan District Hospital
3106 Gibbins Rd.
Duncan, BC V9L 1E8 (Canada)
During gastrointestinal endoscopy, patients may reach a level of sedation that is deeper (i.e. deep sedation) than intended to be (i.e. moderate sedation). In such cases the ability to restore respiratory and cardiovascular function is critical. Supportive measures should be combined with administration of specific pharmacologic antagonists in cases of imminent ventilatory failure. Naloxone rapidly reverses sedation and respiratory depression due to previously administered narcotics, whereas flumazenil overturns the effects of midazolam on the central nervous system. Both agents are administered intravenously in repeated doses according to the patient’s response. Caution, however, is required, as the half-lives of these reversal agents are shorter than those of the respective agonists and re-sedation may occur. Acute withdrawal syndromes may take place in chronic users of opiates or benzodiazepine. Product monographs along with administration protocols may be demonstrated as a wall chart, to ascertain their safe and effective use in endoscopy units.
© 2010 S. Karger AG, Basel
Sedation and analgesia are commonly used in gastrointestinal endoscopy because they minimize patient anxiety, decrease discomfort during the procedure, and create amnesia of the examination. These goals are usually achieved through moderate (or ‘conscious’) sedation, which is the level of sedation used in most endoscopic procedures of the gastrointestinal tract . It is, however, understood that sedation occurs in a continuous scale from anxiolysis to general anesthesia, as defined by various levels of patient alertness, as well as respiratory and cardiovascular function . As a result of this continuum, it is not unusual for patients undergoing endoscopy to reach a level of sedation that is deeper than intended by the agents and dosages administered [3,4]. This, in turn, increases the potential for serious complications, including apnea. In the case of such an occurrence, the ability to reverse deeper levels of sedation should be readily available.
Two classes of sedatives/analgesics have specific antagonists . In particular, the effects of opioids (meperidine and fentanyl) can be reversed with naloxone, whereas flumazenil is a specific antagonist for benzodiazepines and is used to block the action of midazolam.
Naloxone hydrochloride is administered intravenously and will rapidly reverse sedation as well as respiratory depression due to previously administered narcotics . In an oversedated patient, 0.4- to 2.0-mg boluses are given every 2–3 min. If necessary an intravenous infusion can be used . Smaller doses may be appropriate in elders since naloxone induces secretion of catecholamines and may create cardiovascular instability . The duration of treatment depends on the half-life of the narcotic being reversed, as fentanyl has a much shorter T1/2 than meperidine. In fact, naloxone is cleared faster than meperidine. Therefore, the possibility of re-sedation after cessation of naloxone activity should be taken into consideration when large amounts of meperidine have been administered. This should be of particular concern when patient discharge is considered. Caution is also required in chronic opioid abusers, as administration of naloxone can precipitate acute withdrawal syndrome. The latter may include pain, hypertension, tachycardia, and pulmonary edema.
Flumazenil selectively binds to the GABAA receptor complex, prevents the attachment of benzodiazepines to their receptor, and inhibits or reverses their effects on the central nervous system . As a result, flumazenil blocks midazolam- (alone or with opiates) induced sedation and respiratory depression [10,11]. In the oversedated individual, flumazenil is administered through intravenous boluses of 0.2–0.5 mg. A common practice is to administer 0.2 mg over 30 s, and increase to 0.3 mg in the absence of response. Additional repeated doses of 0.5 mg can be given, up to a maximum total of 3 mg. Flumazenil has a rapid onset of action (1–3 min), reaches 80% of the response within 3 min and demonstrates its peak effect in 6–10 min. After intravenous administration, the half-life of flumazenil is between 40 and 80 min. Since the duration of the sedative effect of midazolam may reach 80 min, there is always a possibility for re-sedation of the patient, despite an initial response to flumazenil. Similarly to naloxone, flumazenil can cause acute withdrawal syndrome, including seizures, in patients who receive benzodiazepines chronically . As there is no adequate data for usage of flumazenil in pregnancy, it should be used only when there is an absolute indication .
Reversal agents cannot be relied upon for long-term reversal of sedation, e.g. just prior to discharge, because both naloxone and flumazenil have short half-lives, which can be shorter than the duration on the central nervous system effects of opiates and benzodiazepines, respectively. As a consequence, routine usage of these agents for the reversal of opiate- or benzodiazepine-induced sedation is discouraged by recent guidelines . This, in fact, is reflected in the low utilization of reversal agents in clinical practice. Wehrmann et al.  reported that only 4 of 98 patients who received midazolam during gastrointestinal procedures required flumazenil administration. Similarly, in a nationwide US survey, Cohen et al. [15 ]reported that although sedatives were used in 98.2% of upper gastrointestinal endoscopies and 98.8% of colonoscopies, the frequency of antagonist usage was as low as 0.8%.
Although the routine usage of reversal agents is not recommended, these drugs should be available for use in emergencies, in particular when respiratory depression becomes life-threatening, the patient becomes apneic or hypoxemic, and when intubation and bagging is being considered. In such cases, naloxone or flumazenil administration should always be combined with additional supportive measures: (1) the patients should be encouraged to take deep breaths and supplemental oxygen must be delivered; (2) fluid resuscitation may be necessary in opiate overdosage; (3) if spontaneous ventilation is not sufficient to maintain oxygenation, positive pressure ventilation should not be delayed; and (4) frequent assessment of the patient’s condition is mandatory for continuously evaluating the resuscitating efforts . In addition, special care should be taken in patients in whom problems in maintaining airway control or delivering positive pressure ventilation are expected.
In endoscopy units that administer opiate- and midazolam-based sedation/analgesia, the specific antagonists naloxone and flumazenil should be readily available, as this may be associated with decreased frequency for adverse outcomes. In addition, instructions on how to use them should be accessible and easy to reach. This is particularly relevant for busy endoscopy suites, where personnel may not be familiar with the use of reversal agents, as they rarely use them. In such cases the product monographs may be demonstrated as a wall chart, along with posted administration protocols. These simple measures will facilitate the safe and effective use of reversal agents. Equally important is the need for extended observation of patients after administration of naloxone or flumazenil, as recurrence of central nervous system depression may be observed when the antagonistic effects have ceased.
In conclusion, the use of sedation protocols that incorporate routine use of opioid/benzodiazepine antagonists should be avoided as they may generate a false estimation of the patient’s condition. On the other hand, personnel involved in sedative administration should be familiar with the specifics of each reversal agent and be able to administer it in a timely and safe manner.
Cowichan District Hospital
3106 Gibbins Rd.
Duncan, BC V9L 1E8 (Canada)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.